NYSEHealth CareHealth Care FacilitiesS&P MidCap 400
$137.54
-3.73 (-2.64%)
Close of Nov 06, 2026 · end-of-day data
EHC 8-K filings in 2025
Every material Form 8-K Encompass Health filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Encompass Health reported third-quarter 2025 net operating revenue of $1,477.5 million, up 9.4% from a year earlier, and adjusted earnings per share of $1.23, up from $1.03. The company raised its full-year 2025 guidance for adjusted EBITDA and adjusted EPS, and its revenue range was narrowed. Adjusted free cash flow fell 8.2% in the quarter, to $174.2 million.
Q3 2025 diluted EPS from continuing operations was $1.24, up from $1.07; adjusted EPS was $1.23, up from $1.03.
Q3 adjusted EBITDA was $300.1 million, up 11.4% from $269.3 million; adjusted free cash flow was $174.2 million, down from $189.7 million.
Full-year 2025 adjusted EPS guidance rose to $5.22 to $5.37 from $5.12 to $5.34; adjusted EBITDA guidance rose to $1,235 million to $1,255 million from $1,220 million to $1,250 million.
Full-year 2025 net operating revenue guidance was narrowed to $5,905 million to $5,955 million from $5,880 million to $5,980 million.
Encompass Health said director Patricia Maryland retired from its board of directors effective immediately, citing health reasons. The filing discloses no replacement, financial figures, or change in company operations.
Patricia Maryland informed the company of her retirement decision on September 17, 2025.
Retirement is for health reasons and is effective immediately.
Chairman Greg Carmichael thanked Maryland for her contributions to the board.
Encompass Health reported second-quarter 2025 net operating revenue of $1,457.7 million, up 12.0% from $1,301.2 million a year earlier, and diluted earnings per share from continuing operations of $1.40, up from $1.13. The company raised its full-year 2025 guidance for net operating revenue, adjusted EBITDA and adjusted earnings per share, which gives shareholders a higher outlook for the year.
Q2 2025 net operating revenue was $1,457.7 million, up 12.0%; diluted EPS from continuing operations was $1.40 versus $1.13.
Adjusted EPS was $1.40 versus $1.11 a year earlier; adjusted EBITDA was $318.6 million, up 17.2%.
Full-year 2025 adjusted EPS guidance rose to $5.12 to $5.34 from $4.85 to $5.10; net operating revenue guidance rose to $5,880 to $5,980 million.
Management will discuss results on an earnings call at 10:00 a.m. Eastern Time on August 5, 2025.
At its May 1, 2025 annual meeting, Encompass Health stockholders passed all four proposals: electing 10 directors, ratifying PricewaterhouseCoopers LLP as auditor, approving named executive officer compensation, and approving the 2025 Omnibus Performance Incentive Plan. The filing reports vote results and attaches the incentive plan as Exhibit 10.1, which shareholders can review for its terms.
All 10 director nominees were elected; Greg D. Carmichael received 87,805,760 votes for and 2,107,016 against.
PwC ratification passed with 91,374,755 votes for and 3,403,771 against.
Named executive officer compensation approval passed with 87,426,450 votes for and 2,187,504 against.
2025 Omnibus Performance Incentive Plan passed with 85,524,738 votes for and 4,376,186 against, plus 4,876,924 broker non-votes.
Encompass Health reported first-quarter 2025 net operating revenue of $1.46 billion, up 10.6% from a year earlier, and diluted earnings per share from continuing operations of $1.48, up from $1.11. The company raised its full-year 2025 adjusted earnings per share guidance to $4.85 to $5.10, from $4.67 to $4.96, and also named Patrick W. Tuer as Executive Vice President and Chief Operating Officer.
Q1 2025 net operating revenue was $1,455.4 million, up 10.6% from $1,316.0 million in Q1 2024.
Diluted EPS from continuing operations was $1.48 versus $1.11; adjusted EPS was $1.37 versus $1.12.
Full-year 2025 guidance raised: adjusted EPS to $4.85 to $5.10 (from $4.67 to $4.96) and adjusted EBITDA to $1,185 million to $1,220 million (from $1,160 million to $1,200 million).
Patrick W. Tuer, age 41, appointed EVP and COO with a $450,000 base salary; the earnings call is at 9:00 a.m. Eastern on April 25, 2025.
At meetings on February 19-20, 2025, the board and its Compensation and Human Capital Committee approved annual 2025 pay increases for CEO Mark Tarr and three other named executive officers. For Tarr, base salary rises to $1.1 million, target cash bonus to $1.485 million, and target long-term equity to $6 million, and his annual personal aircraft-use allowance rises from approximately $75,000 to $100,000. The filing describes these as routine annual decisions and does not report any change in financial results, but the higher pay levels add to executive compensation costs.
Tarr's base salary rises from $1,050,000 to $1,100,000; target cash bonus from $1,260,000 to $1,485,000; target long-term equity from $5,425,000 to $6,000,000.
Tarr's annual personal aircraft-use allowance rises from approximately $75,000 to $100,000.
CFO Douglas Coltharp's base salary rises from $700,000 to $750,000; target long-term equity from $1,925,000 to $2,250,000.
Decisions were made at February 19-20, 2025 meetings, on the recommendation of the Compensation and Human Capital Committee and its independent consultant.
Encompass Health reported fourth-quarter 2024 net operating revenue of $1,405.0 million, up 12.7%, and diluted earnings per share from continuing operations of $1.18, up from $0.94 a year earlier. The company also issued 2025 guidance for net operating revenue of $5,800 million to $5,900 million, Adjusted EBITDA of $1,160 million to $1,200 million, and adjusted earnings per share of $4.67 to $4.96.
Q4 2024 net operating revenue was $1,405.0 million, up from $1,246.8 million; diluted EPS from continuing operations was $1.18 versus $0.94
Q4 2024 Adjusted EBITDA was $289.6 million, up 13.6%; adjusted EPS was $1.17 versus $0.95
2025 guidance: net operating revenue $5,800 million to $5,900 million; Adjusted EBITDA $1,160 million to $1,200 million; adjusted EPS $4.67 to $4.96
Management will discuss results on an earnings call at 10:00 a.m. Eastern Time on February 7, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Encompass Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →